Page last updated: 2024-08-16

ribavirin and vancomycin

ribavirin has been researched along with vancomycin in 12 studies

Research

Studies (12)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (25.00)29.6817
2010's7 (58.33)24.3611
2020's2 (16.67)2.80

Authors

AuthorsStudies
Lombardo, F; Obach, RS; Waters, NJ1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV1
Batta, G; Herczegh, P; Kéki, S; Komáromi, I; Mándi, A; Naesens, L; Ostorházi, E; Pintér, G; Röth, E; Rozgonyi, F; Sztaricskai, F; Takács-Novák, K1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ1
Ekins, S; Williams, AJ; Xu, JJ1
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V1
Batta, G; Bereczki, I; Borbás, A; Herczegh, P; Jóna, I; Kéki, S; Máté, G; Naesens, L; Ostorházi, E; Rőth, E; Rozgonyi, F; Sipos, A; Vanderlinden, E1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Jones, LH; Nadanaciva, S; Rana, P; Will, Y1
Ghorat, F; Kalan Farmanfarma, K; Mahdavifar, N; Moslem, A; Nematshahi, M; Salehiniya, H1
Aghajani, F; Akhavizadegan, H; Dolatkhani, F; Faghir Gangi, M; Ghasemi, H; Ghazi, Z; Mousavi Movahed, SM; Nejadghaderi, SA1

Reviews

1 review(s) available for ribavirin and vancomycin

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

11 other study(ies) available for ribavirin and vancomycin

ArticleYear
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Physicochemical determinants of human renal clearance.
    Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15

    Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight

2009
Diazo transfer-click reaction route to new, lipophilic teicoplanin and ristocetin aglycon derivatives with high antibacterial and anti-influenza virus activity: an aggregation and receptor binding study.
    Journal of medicinal chemistry, 2009, Oct-08, Volume: 52, Issue:19

    Topics: Anti-Bacterial Agents; Antiviral Agents; Diazonium Compounds; Doxorubicin; Gram-Positive Bacteria; Microbial Sensitivity Tests; Orthomyxoviridae; Teicoplanin

2009
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Developing structure-activity relationships for the prediction of hepatotoxicity.
    Chemical research in toxicology, 2010, Jul-19, Volume: 23, Issue:7

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes

2010
A predictive ligand-based Bayesian model for human drug-induced liver injury.
    Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12

    Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands

2010
FDA-approved drug labeling for the study of drug-induced liver injury.
    Drug discovery today, 2011, Volume: 16, Issue:15-16

    Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration

2011
Synthesis of fluorescent ristocetin aglycon derivatives with remarkable antibacterial and antiviral activities.
    European journal of medicinal chemistry, 2012, Volume: 58

    Topics: Anti-Bacterial Agents; Antiviral Agents; Dose-Response Relationship, Drug; Doxorubicin; Fluorescence; Gram-Positive Bacteria; Microbial Sensitivity Tests; Molecular Conformation; Orthomyxoviridae; Structure-Activity Relationship

2012
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
    Bioorganic & medicinal chemistry letters, 2016, 08-15, Volume: 26, Issue:16

    Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone

2016
The index case of COVID-19 in Northeastern Iran.
    Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace, 2020, Dec-03, Volume: 90, Issue:4

    Topics: Adult; Aged, 80 and over; Anti-Bacterial Agents; Antiviral Agents; Contact Tracing; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Humans; Iran; Male; Quarantine; Respiratory Distress Syndrome; Ribavirin; SARS-CoV-2; Tomography, X-Ray Computed; Travel-Related Illness; Treatment Outcome; Vancomycin

2020
Different incidences of acute kidney injury (AKI) and outcomes in COVID-19 patients with and without non-azithromycin antibiotics: A retrospective study.
    Journal of medical virology, 2021, Volume: 93, Issue:7

    Topics: Acute Kidney Injury; Adult; Angiotensin-Converting Enzyme Inhibitors; Antiviral Agents; Azithromycin; Coinfection; COVID-19; COVID-19 Drug Treatment; Critical Care; Drug Combinations; Female; Hospital Mortality; Hospitalization; Humans; Iran; Linezolid; Lopinavir; Male; Middle Aged; Retrospective Studies; Ribavirin; Ritonavir; SARS-CoV-2; Treatment Outcome; Vancomycin

2021